Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

ConclusionThe results of this trial, which provide insights into the CV safety of tocilizumab as compared to etanercept, ruled out a risk for occurrence of MACE of 1.43 or higher in patients treated with tocilizumab. This result should be interpreted in the context of the clinical efficacy and non ‐CV safety of tocilizumab.

Source: Arthritis and Rheumatology - December 26, 2019 Category: Rheumatology Authors: Jon T. Giles, Naveed Sattar, Sherine Gabriel, Paul M. Ridker, Steffen Gay, Charles Warne, David Musselman, Laura Brockwell, Emma Shittu, Micki Klearman, Thomas R. Fleming Tags: Original Article Source Type: research